Neuromuscular Disorders
Drug-induced myasthenic syndromes
May. 21, 2026
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Peripheral nerve hyperexcitability syndromes
- Updated 05.26.2025
- Released 08.24.2022
- Expires For CME 05.26.2028
Peripheral nerve hyperexcitability syndromes
Introduction
Overview
Peripheral nerve hyperexcitability syndromes are a group of disorders that share clinical and electrodiagnostic features of motor nerve instability. However, their clinical presentations and phenotypes are varied. Common symptoms of peripheral nerve hyperexcitability syndromes, including muscle stiffness, twitches, and spasms, are also shared with certain central nervous system and myopathic conditions. Cramp-fasciculation syndrome, Isaacs syndrome, and Morvan syndrome are the most accepted terms, though prior terminology has been confusing. More recent investigations have led to an understanding of the autoimmune mechanisms of these rare conditions; their specific associated antibodies, including voltage-gated potassium channel-complex antibodies; and associated neoplasms. The evaluation of peripheral nerve hyperexcitability syndromes requires familiarity with the spectrum of symptoms associated with them, recognition of their diagnostic electrodiagnostic features, understanding their autoimmune pathogenesis, and their optimal treatment.
Key points
|
• Symptoms of Isaacs syndrome include muscle stiffness, muscle twitches/clinical myokymia, and autonomic symptoms. Morvan syndrome is similar to Isaacs syndrome but with additional autonomic and encephalopathy symptoms. | |
|
• Electrodiagnostic findings in peripheral nerve hyperexcitability syndromes include fasciculation potentials, doublets, triplets, multiplets, myokymic discharges, and neuromyotonic discharges. Stimulus-induced after-discharges (SIAD) on motor nerve conduction studies may also be seen. | |
|
• Antibodies to voltage-gated potassium channel (VGKC)-complex proteins directed against contactin-associated protein-2 (CASPR2) or leucine-rich glioma-inactivated 1 (LGI1) may be elevated in peripheral nerve hyperexcitability syndromes. | |
|
• Isaacs and Morvan syndromes may be associated with malignancy, including thymoma and small cell lung carcinoma. VGKC-complex antibody seropositive patients may have a higher incidence of malignancy. | |
|
• Peripheral nerve hyperexcitability syndromes respond to treatment with membrane-stabilizing drugs, such as carbamazepine, phenytoin, and gabapentin. | |
|
• In moderate to severe cases, corticosteroids and immunomodulatory treatment are necessary. Plasma exchange or infusion of intravenous immunoglobulin provide symptomatic relief, often supplementing corticosteroids or immunosuppressive steroid-sparing therapy. | |
|
• The prognosis of peripheral nerve hyperexcitability syndromes is good, and the majority of patients improve with remission in about 5 years. |
Historical note and terminology
In 1888 and 1895, Kny and Schutze, respectively and independently, described continuous muscle twitches and quoted the term “myokymia” (myo = muscle, kyma = wave in Greek).
In 1890, Augustin Morvan described “la chorée fibrillaire” associated with autonomic dysfunction and severe insomnia.
In 1948, Denny-Brown and Foley first described generalized myokymia and identified the electrical correlate of this activity consisting of continuous, irregular discharges from different motor units (06).
In 1961, Isaacs described a clinical syndrome in which generalized myokymia was a prominent component. He later showed that the myokymia was not eliminated by blockade of the peripheral nerve but that it could be eliminated by curare. He suspected that motor activity originates from the distal segments of motor axons of peripheral nerves (13; 14).
In 1965, Mertens and Zschocke coined the term “neuromyotonia” to highlight the peripheral nerve origin of the myotonia-like muscle discharges (22).
The terminology and clinical phenomenology of peripheral nerve hyperexcitability syndromes, which significantly overlap, have been confusing. The medical literature has used multiple terms to describe peripheral nerve hyperexcitability syndromes, including idiopathic generalized myokymia, acquired neuromyotonia, Armadillo syndrome, syndrome of continuous muscle fiber activity, la chorée fibrillaire, and quantal squander. To add to this confusion, the electrophysiological terms, including myokymia, neuromyotonia, continuous muscle fiber activity, continuous motor neuron discharges, and neurotonia, are used interchangeably and in an inconsistent fashion.
Despite the presence of several distinguishing clinical and electrophysiological features of peripheral nerve hyperexcitability syndromes, a significant overlap exists among the three main peripheral nerve hyperexcitability syndromes: Isaacs syndrome, Morvan syndrome, and cramp-fasciculation syndrome.
Clinical manifestations
Presentation and course
Cramp-fasciculation syndrome. Cramp-fasciculation syndrome is a benign syndrome that presents with myalgia and cramps without weakness (30; 21). Examination may show fasciculations, myokymia, or both in muscles with an otherwise normal neuromuscular examination. The calves may become large.
Isaacs syndrome. Isaacs syndrome may affect patients at any age. It often manifests with generalized muscle stiffness that fluctuates but usually slowly worsens over the years. The stiffness persists during sleep (15; 01). On examination, there is continuous muscle twitching and undulation. Sometimes, muscle hypertrophy (mainly calf muscles) may be evident. The disorder varies significantly in severity. When severe, there is slowness of movement, and posture may be rigid. Trousseau and Chvostek signs may be present, and dysarthria and dysphagia may occur. Hyperhidrosis, sialorrhea, piloerection (goose flesh), and abdominal pain may also be present. Sensory manifestations are rare and include paresthesia and neuropathic pain.
Morvan syndrome. Morvan syndrome affects males more than females. It mimics Isaacs syndrome but includes additional features, such as neuropathic limb pain (likely due to involvement of small sensory fibers), sleep disturbances (mostly insomnia), and dysautonomia (12). Hyperhidrosis, tachycardia, cardiac arrhythmias, and urinary dysfunction are common dysautonomia symptoms. CNS features, including hallucinations, agitation, delirium, amnesia, and confusion, may also occur.
Limbic encephalitis. A discussion of the peripheral nerve hyperexcitability syndromes is not complete without addressing limbic encephalitis, which overlaps with peripheral nerve hyperexcitability syndromes (Table 1).
Table 1. Characteristic Clinical Findings in Patients with Peripheral Nerve Hyperexcitability Syndromes and Limbic Encephalitis
|
Cramp fasciculation syndrome |
Isaacs syndrome |
Morvan syndrome |
Limbic encephalitis | |
|
Muscle stiffness |
+ |
++ |
++ |
- |
|
Muscle twitching |
++ |
++ |
++ |
+ / - |
|
Muscle cramps |
++ |
++ |
++ |
- |
|
Fasciculation potentials |
++ |
+ |
+ |
+ / - |
|
Myokymic discharges |
- |
++ |
++ |
+ / - |
|
Neuromyotonic discharges |
- |
++ |
+++ |
+ / - |
|
Autonomic features |
- |
++ |
++ |
+ |
|
Agitation |
- |
- |
++ |
++ |
|
Memory loss |
- |
- |
+ |
++ |
|
Insomnia |
- |
- |
+ |
++ |
|
Faciobrachial dystonic seizures |
- |
- |
- |
++ |
|
Brain MRI changes |
- |
- |
- |
++ |
|
CASPR2 antibodies |
+ / - |
+ |
++ |
+ |
|
LGI1 antibodies |
- |
+ / - |
+ |
++ |
Autoimmune limbic encephalitis may be paraneoplastic or nonparaneoplastic, with significant overlap. The majority have antibodies towards intracellular antigens (eg, Hu, Ma2, or GAD65) or neuronal cell-surface proteins, ion channels, or receptors (such as N-methyl-d-aspartate receptor [NMDAR], VGKC-complex antibodies [including LGI1 and CASPR2], γ-aminobutyric acid type B receptor [GABABR], or α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor [AMPAR]).
Limbic encephalitis associated with voltage-gated potassium channel-complex antibodies (VGKC-complex antibodies) is the second most frequent autoimmune encephalitis. This encephalitis is specifically associated with leucine-rich glioma-inactivated 1 (LGI1) antibody and less commonly with contactin-associated protein-like 2 (CASPR2). This predominantly CNS disorder frequently presents with multiple faciobrachial dystonic seizures before developing the amnestic and behavioral manifestations of limbic encephalitis (33). Dysautonomia, neuropathic pain, and peripheral nerve hyperexcitability (fasciculations, myokymia, and neuromyotonia) may accompany limbic encephalitis, hence, overlapping with peripheral nerve hyperexcitability syndromes, particularly Morvan syndrome. These peripheral manifestations are more commonly seen when limbic encephalitis is associated with CASPR2 than LGI1 antibodies. Additional diagnostic findings include MRI FLAIR-T2 imaging showing bilateral abnormalities highly restricted to the medial temporal lobes, CSF pleocytosis, and epileptic features or slow activity originating from the temporal lobes on EEG.
Prognosis and complications
Peripheral nerve hyperexcitability syndromes have a favorable prognosis. Up to 80% of patients respond favorably to corticosteroids combined with a membrane stabilizer, such as carbamazepine or phenytoin. In the majority of patients, immunosuppressive therapy, if used, can be stopped in 1 to 5 years (19).
Biological basis
Etiology and pathogenesis
Voltage-gated potassium channels (VGKCs) are central to the pathophysiology of peripheral nerve hyperexcitability syndromes. Blockade of VGKCs increases nerve excitability and may lead to spontaneous repetitive peripheral nerve discharges in peripheral nerve hyperexcitability disorders, including muscle cramps, muscle twitches, fasciculations, myokymia, and neuromyotonia.
Immunology and pathophysiology. Earlier clinical observations suggested an autoimmune pathogenesis to the peripheral nerve hyperexcitability syndromes. This included the strong association with other autoimmune disorders, mostly myasthenia gravis, but also Hashimoto thyroiditis, celiac disease, and connective tissue disorders.
Further investigations have confirmed the presence of IgG4 autoantibodies directed against voltage-gated potassium channel (VGKC) complex, specifically LGI1 and CASPR2. CASPR2 antibodies destabilize the voltage-gated potassium channel complex into the membrane, whereas LGI1 antibodies alter the binding of LGI1 with its postsynaptic cell membrane receptor, a disintegrin and metalloproteinase 22 (ADAM22). LGI1 protein has a predominant hippocampal localization, whereas CASPR2 is localized to the juxtaparanodal region of myelinated nerves, findings that explain the predilection of LGI1-positive patients to CNS manifestations and CASPR2 patients to peripheral nerve hyperexcitability manifestations (11).
Epidemiology
Peripheral nerve hyperexcitability syndromes are rare, and their incidence is not known. The annual incidence of anti-LGI1 limbic encephalitis in the Netherlands is 0.83 per million (34).
Heredity
Episodic ataxia type 1 and HINT1 Charcot-Marie-Tooth disease are two inherited disorders associated with peripheral nerve hyperexcitability manifestations.
Episodic ataxia type 1. Episodic ataxia type 1 is an inherited channelopathy disorder associated with peripheral nerve hyperexcitability manifestations. It is autosomal dominant and mapped to chromosome 12p13; the responsible gene is KCNA1 (05). All mutations impair Kv1.1 function, a delayed-rectifier potassium channel responsible for repolarizing nerves after depolarization. This potassium channel is abundantly expressed in the cerebellum and in motor axons, resulting in increased neuronal excitability.
Episodic ataxia type 1 often manifests before the age of 20. It is characterized by brief episodes of ataxia, dysarthria, coarse tremor, dizziness or vertigo, and muscle stiffness, weakness, and twitching (17). Nausea, vomiting, and headache are rare. The attacks are often precipitated by physical exertion, emotional stress, or environmental temperature. They usually last a few minutes to, rarely, hours and range from daily to monthly. About 20% of patients with episodic ataxia type 1 accumulate persistent cerebellar ataxia (09).
Myokymia is usually persistent at baseline but worsens during the attacks. It is not clear whether the tremors and muscle twitching represent exacerbation of interictal myokymia. Myokymia may be detected clinically or may only be apparent by needle EMG, which often shows both myokymic and neuromyotonic discharges.
Acetazolamide, a carbonic-anhydrase inhibitor, may reduce the frequency and severity of the ataxic attacks in some patients. Carbamazepine and valproic acid are sometimes effective (17). Avoiding stress, abrupt movements, loud noises, and caffeine intake are important measures to reduce the severity and frequency of attacks.
HINT1 Charcot-Marie-Tooth disease. An axonal, predominantly motor Charcot-Marie-Tooth disease is an autosomal recessive neuropathy associated with neuromyotonia, which is present, at least electrically, in 70% to 80% of patients (27). It is caused by the loss-of-function mutations in histidine triad nucleotide binding protein 1 (HINT1), which is ubiquitously expressed in the peripheral nerves and may have a role in signaling and transcriptional pathways. HINT1-related hereditary neuropathy often presents in the first 1 to 2 decades of life with gait disorder and distal leg and hand weakness and atrophy, with frequent hand contractures. There are often muscle cramps and stiffness, particularly in the hands. Sensory loss is subtle or absent. EMG shows both neuromyotonic and myokymic discharges, which, when present, distinguish this hereditary neuropathy from other types of Charcot-Marie-Tooth disease. The disorder is slowly progressive.
Differential diagnosis
Confusing conditions
Muscle stiffness is a common presenting symptom and is often caused by a variety of peripheral nervous system disorders, such as myopathies and peripheral nerve hyperexcitability syndromes, and central nervous system disorders, such as stiff-person syndrome.
Nondystrophic myotonias. Nondystrophic myotonias, specifically myotonia congenita, often present with muscle stiffness that manifests when attempting to initiate movement after a period of rest and diminishes with repeated activity and muscle contractions (29). Needle EMG shows prominent myotonic discharges without myopathic motor unit action potential changes.
Dystrophic myotonias. Dystrophic myotonias, including myotonic dystrophy type 1 and type 2, often present with muscle weakness but may have stiffness and muscle pain. These disorders have frequent nonmuscular manifestations that help establish the diagnosis, including cataracts, cardiac conduction defects, balding, temporal atrophy, and characteristic hatchet facies (29). The needle EMG shows characteristic myotonic discharges as well as short duration, low-amplitude, and polyphasic motor unit action potentials.
Schwartz-Jampel syndrome. Schwartz-Jampel syndrome, or chondrodystrophic myotonia, is a rare autosomal recessive disorder characterized by the triad of myotonia, facial dysmorphism, and skeletal deformities. Common features include muscle stiffness, hypertrophy, and contractures as well as clinical myotonia (03). Other features are facial dysmorphisms, including puckered-small mouth, blepharophimosis and blepharospasm, and skeletal abnormalities, including short stature, kyphosis, hip dysplasias, and pseudofractures. Muscle enzymes are normal or slightly elevated. Nerve conduction studies are normal. Needle EMG reveals continuous myotonic discharges at rest. The disorder results from mutations in the HSPG2 gene in chromosome 1p34-36.1, which encodes perlecan, a major component of basement membranes.
Rippling muscle disease. Rippling muscle disease is a benign myopathy with symptoms and signs of muscular hyperexcitability. The typical finding is a rolling, wave-like mounding of muscle provoked by mechanical stimuli and stretch that is electrically silent on needle EMG recording (32). The disorder has immune associations, including acetylcholine receptor–antibody positive myasthenia gravis and thymoma. Immune rippling muscle disease patients have autoantibodies to caveolae-associated protein 4 (cavin-4) (07; 28). Hereditary rippling muscle disease patients have autosomal dominant mutations in the gene encoding caveolin-3 (CAV3), a membrane-associated protein localized to skeletal muscle fibers, or autosomal recessive mutations of the cavin-1 genes. Muscle biopsies demonstrate a mosaic or diffuse pattern of caveolin-3 deficiency.
Stiff-person syndrome. Stiff-person syndrome is a central nervous system disorder characterized by progressive and fluctuating muscle stiffness, with painful muscle spasms in the limbs, trunk, and neck (31). The disorder is associated with HLA phenotypes predisposing to type 1 diabetes, epilepsy, and other organ-specific autoimmunity. Affected muscles become tight and rock-hard during episodes. In severe cases, there is lumbar hyperlordosis and gait stiffness. In more than 70% of patients, antibodies are detected in serum directed against glutamic acid decarboxylase (GAD), the enzyme responsible for the biosynthesis of GABA. In about 5% of patients, anti-amphiphysin antibodies are seen in serum and CSF, and their presence in women can be associated with breast cancer. The needle EMG in stiff-person syndrome reveals nonspecific, continuous normal motor unit activity at rest, sometimes seen concomitantly in agonist and antagonist muscles. These manifestations are abolished by sleep, anesthesia, peripheral nerve blockade, and curare.
Associated or underlying disorders
A malignancy may precede or follow peripheral nerve hyperexcitability syndromes, mostly those with detectable VGKC-complex antibodies. The incidence of malignancy varies from 10% to 47% and occurs mostly in patients over 45 years of age (16). The majority of patients have thymoma, with occasional patients having lung or colon cancer.
Patients with peripheral nerve hyperexcitability syndromes, more specifically, Morvan syndrome and malignant thymoma, may also be associated with acetylcholine receptor antibody-positive myasthenia gravis.
Diagnostic workup
The diagnosis of peripheral nerve hyperexcitability syndromes requires a high index of suspicion and is often supported by laboratory and electrophysiological findings.
Laboratory findings. The majority of patients with peripheral nerve hyperexcitability syndromes, mostly Isaacs syndrome and Morvan syndrome, and occasionally cramp-fasciculation syndrome, have CASPR2 autoimmunity, whereas patients with limbic encephalitis and epilepsy (mostly faciobrachial dystonic seizures) often have LGI1 autoimmunity. These antibodies target surface-exposed CASPR2 or LGI1 domains of voltage-gated potassium channel (VGKC). However, this is not exclusive; significant overlap exists, with neuropathic pain, cerebellar syndrome, and epilepsy frequently occurring in a significant number of patients with Caspr2 autoimmunity and peripheral nerve hyperexcitability syndromes occurring in some patients with LGI1 autoimmunity.
Voltage-gated potassium channel (VGKC)-complex antibodies with LGI1 or CASPR2 reactivity are more specific and appear to be directly pathogenic compared to VGKC antibodies. Low-level VGKC-complex antibodies and VGKC antibodies are less specific and present in a variety of nonspecific disorders (16; 23). Among sera with positive VGKC antibodies, only 15% have LGI1 and CASPR2 pathogenic antibodies (23). The clinical significance of low VGKC complex IgG values with negative LGI1 and CASPR2 antibodies remains to be defined (20). It is also possible that unrecognized antibodies that contribute to the development of peripheral nerve hyperexcitability syndromes exist.
Electrophysiological findings. The electrophysiological findings of peripheral nerve hyperexcitability syndromes are the core findings in the diagnosis. This includes findings on nerve conduction studies and needle electromyographic (EMG) examination.
Needle EMG. A variety of spontaneous motor unit activities are seen with peripheral nerve hyperexcitability syndromes on needle EMG. This mostly includes fasciculation potentials, doublets/triplets/multiplets, myokymic discharges, and neuromyotonic discharges (18). These abnormal discharges originate from one or more segments of the peripheral motor axon (10). They are not blocked by general anesthesia but are eliminated by neuromuscular junction blockade.
Fasciculation potentials are spontaneous (involuntary) discharges of individual motor units. They originate from the anterior horn cell or motor axon anywhere along its length. Fasciculation potentials fire randomly and irregularly, with variable waveform morphology and at a much slower firing rate than voluntary motor unit action potentials. They may be associated with visible muscle twitches and, rarely, in slight movements of small joints in the fingers or toes. When abundant, fasciculation potentials give a “popping corn” sound on the EMG loudspeaker.
Doublets, triplets, and multiplets are spontaneous motor unit action potentials that fire in groups of two, three, or multiple potentials. They have the same significance as fasciculations.
A myokymic discharge is a grouped discharge of one or a few motor unit action potentials occurring spontaneously and repetitively in a quasi-rhythmical fashion at rates of 1 to 5 Hz, which gives the myokymic discharge the sound of “marching soldiers” on the loudspeaker. The burst is composed of about 2 to 15 spikes, with frequent variability in the number of spikes per discharge.
A neuromyotonic discharge includes bursts of a single motor unit action potential firing at very high frequency of 150 to 250 Hz for several seconds, often starting and stopping abruptly, and with decrementing amplitudes and frequency.
Both neuromyotonic and myokymic discharges may be detected in patients with peripheral nerve hyperexcitability syndromes, including Isaacs and Morvan syndromes, as well as in limbic encephalitis. However, neuromyotonic discharges are more specific for the peripheral nerve hyperexcitability syndromes, whereas myokymic discharges occur in many other settings. Myokymic discharges may be seen either focally or in a more generalized fashion in many other peripheral nerve disorders. This includes radiation plexopathy, carpal tunnel syndrome, Guillain-Barré syndrome, gold toxicity, pontine glioma, and multiple sclerosis (Table 2).
Table 2. Causes of Myokymia
|
Generalized myokymia |
Limb myokymia |
Facial myokymia |
|
Peripheral nerve hyperexcitability syndromes (Isaacs and Morvan syndromes) |
Radiation plexopathy |
Multiple sclerosis |
|
Limbic encephalitis | ||
|
Heavy metal exposure (gold, platinum compounds, lithium, mercury, or manganese) |
Carpal tunnel syndrome |
Brainstem mass lesion |
|
Penicillamine therapy |
Ulnar mononeuropathy |
Cerebellopontine angle mass lesion |
|
Timber rattlesnake venom |
Peripheral nerve injury |
Basilar invagination |
|
Thyrotoxicosis |
Radiculopathy |
Syringobulbia |
|
Guillain-Barré syndrome |
Guillain-Barré syndrome |
Obstructive hydrocephalus |
|
Bell palsy |
Chronic inflammatory demyelinating polyneuropathy | |
|
Charcot-Marie-Tooth disease | ||
|
Amyotrophic lateral sclerosis |
Nerve conduction studies. The findings on nerve conduction studies have generally been ignored in peripheral nerve hyperexcitability syndromes. Stimulus induced after discharges (SIAD) are repetitive or sustained firing of action potentials that occur after supramaximal stimulation of motor nerves and persist beyond stimulus cessation. These repetitive late potentials are seen following the initial compound muscle action potential. They are detected in 15% to 40% of patients with peripheral nerve hyperexcitability syndromes during routine motor nerve conduction studies. However, they are seen in up to 75% when higher gain setting (200 uV/division) and time base (20 ms/division) are utilized, such as during F wave studies (04; 24). SIADs are best seen during tibial F wave studies.
SIAD is best measured as the mean F wave duration as a marker of excitability of the peripheral nerve. This is markedly prolonged in peripheral nerve hyperexcitability syndromes, averaging 54.2 +/- 11.0 msec, compared to controls (16.8 +/- 1.8 msec) (24). SIAD are reported to be more sensitive than abnormal spontaneous discharges detected by needle EMG (26; 24). However, SIADs following repetitive nerve stimulation at various frequencies (between 2 and 20 Hz) in patients with peripheral nerve hyperexcitability syndromes may not necessarily distinguish patients with peripheral nerve hyperexcitability from controls and is under debate.
Management
The management of peripheral nerve hyperexcitability syndromes includes symptomatic treatment, immunomodulation treatment, and malignancy detection and therapy (08).
Symptomatic treatment is designed to reduce spontaneous peripheral nerve discharges by altering their channel properties (Table 3). Membrane-stabilizing agents, such as sodium channel-blocking agents and, more specifically, carbamazepine or phenytoin, are often the first line of treatment and most effective in reducing muscle stiffness, twitching, and cramps (02). Carbamazepine at 200 to 400 mg/day in divided doses, with a maximum daily dose of 1600 mg, is often successful. Adverse effects include hyponatremia, blood dyscrasias, and hepatotoxicity. Phenytoin at a single daily dose of 300 to 600 mg is a good alternative to carbamazepine. Adverse effects include blood dyscrasias, osteoporosis, and gingival hypertrophy. Other sodium channel-blocking agents, such as lamotrigine, lacosamide, valproate, and oxcarbazepine, may also be used. Gabapentinoids, such as gabapentin and pregabalin, are also used and can be effective in symptoms relief. These agents possess membrane-stabilizing effects by direct/indirect action on sodium channels and inhibition of neuronal hyperactivity. Mexiletine, dantrolene, baclofen, and acetazolamide have been used with variable success.
Corticosteroids are effective. The majority of patients (about 80%) respond favorably to corticosteroids combined with a membrane stabilizer (19). Oral corticosteroids are often satisfactory, but in severe nonambulatory patients, intravenous methylprednisolone is recommended initially and then switched to an oral corticosteroid after 3 to 5 days. This could also later be switched to a steroid-sparing agent, such as azathioprine, mycophenolate, cyclosporine, or cyclophosphamide.
Immunomodulation and more aggressive immunosuppressive therapies are usually reserved for patients who are nonresponders to corticosteroids combined with a membrane stabilizer or those with severe motor, autonomic, or CNS symptoms. Intravenous immunoglobulin, plasmapheresis, and rituximab have all been used and are reported to be effective (25). Maintenance therapy with immunosuppressive therapy or combination therapy is often needed to avoid the recurrence of symptoms. However, in the majority of patients, immunosuppressive therapy could be stopped in 1 to 5 years.
Search, detection, and treatment of underlying malignancy, specifically thymoma, is indicated and help to alleviate the manifestations of the underlying peripheral nerve hyperexcitability syndrome.
Table 3. Symptomatic Treatment of Peripheral Nerve Hyperexcitability Syndromes
|
Sodium channel-blocking agents | |
|
• Carbamazepine | |
|
Gabapentinoids | |
|
• Gabapentin | |
|
Miscellaneous agents | |
|
• Acetazolamide | |
Outcomes
Peripheral nerve hyperexcitability syndromes are treatable disorders, and three quarters of patients respond to symptomatic and immunomodulation therapy, or both. In most patients, immunosuppressive therapy can be stopped in 1 to 5 years (19). However, a relapse may occur in up to a quarter of patients (34). Patients with LGI1 antibodies and CNS manifestations may have residual memory loss (33).
Media
References
- 01
- Ahmed A, Simmons Z. Isaacs syndrome. A review. Muscle Nerve 2015;52(1):5-12. PMID 25736532
- 02
- Al-Chalabi M, Hegde P, Moore SR, et al. Systematic review of the clinical characteristics and management of Isaac syndrome. J Clin Neuromuscul Dis 2023;25(2):94-106. PMID 37962197
- 03
- Basiri K, Fatehi F, Katirji B. The Schwartz-Jampel syndrome: case report and review of literature. Adv Biomed Res 2015;4:163. PMID 26436077
- 04
- Bodkin CL, Kennelly KD, Boylan KB, Crook JE, Heckman MG, Rubin DI. Defining normal duration for afterdischarges with repetitive nerve stimulation: a pilot study. J Clin Neurophysiol 2009;26(1):45-9. PMID 19151616
- 05
- Chen H, von Hehn C, Kaczmarek LK, Ment LR, Pober BR, Hisama FM. Functional analysis of a novel potassium channel (KCNA1) mutation in hereditary myokymia. Neurogenetics 2007;8(2):131-5. PMID 17136396
- 06
- Denny-Brown D, Foley DM. Myokymia and benign fasciculations of muscular cramps. Trans Assoc Am Physicians 1948;61:88-96.
- 07
- Dubey D, Beecher G, Hammami MB, et al. Identification of caveolae-associated protein 4 autoantibodies as a biomarker of immune-mediated rippling muscle disease in adults. JAMA Neurol 2022;79(8):808-16. PMID 35696196
- 08
- Elangovan C, Morawo A, Ahmed A. Current treatment options for peripheral nerve hyperexcitability syndromes. Curr Treat Options Neurol 2018;20(7):23. PMID 2988385
- 09
- Graves TD, Cha YH, Hahn AF, et al. Episodic ataxia type 1: clinical characterization, quality of life and genotype-phenotype correlation. Brain 2014;137(Pt 4):1009-18. PMID 24578548
- 10
- Harik SI, Baraka AS, Tomeh GF, Mire-Salman J, Kronful Z, Afifi AK. Autonomous peripheral nerve activity causing generalized muscle stiffness and fasciculations: report of a case with physiological, pharmacological, and morphological observations. Johns Hopkins Med J 1976;139 (Suppl):49-60. PMID 189112
- 11
- Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain 2010;133(9):2734-48. PMID 20663977
- 12
- Irani SR, Pettingill P, Kleopa KA, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol 2012;72(2):241-55. PMID 22473710
- 13
- Isaacs H. A syndrome of continuous muscle fiber activity. J Neurol Neurosurg Psychiatry 1961;24(4):319-25. PMID 21610902
- 14
- Isaacs H. Continuous muscle fiber activity in an Indian male with additional evidence of terminal motor fiber abnormality. J Neurol Neurosurg Psychiatry 1967;30(2):126-33. PMID 6034105
- 15
- Jamieson PW, Katirji MB. Idiopathic generalized myokymia. Muscle Nerve 1994;17(1);42-51. PMID 8264701
- 16
- Jammoul A, Shayya L, Mente K, Li J, Rae-Grant A, Li Y. Clinical utility of seropositive voltage-gated potassium channel-complex antibody. Neurol Clin Pract 2016;6(5):409-18. PMID 27847683
- 17
- Jen JC, Graves TD, Hess EJ, et al. Primary episodic ataxias: diagnosis, pathogenesis and treatment. Brain 2007;130(Pt 10);2484:93. PMID 17575281
- 18
- Katirji B. Peripheral nerve hyperexcitability. Handb Clin Neurol 2019;161:281-90. PMID 31307606
- 19
- Khadilkar S, Pandya D, Dhonde P, et al. Acquired hyperexcitable peripheral nerve disorders: clinical and laboratory features, therapeutic responses, and long-term follow-up. Muscle Nerve 2024;69(1):48-54. PMID 37936515
- 20
- Klein CJ, Lennon VA, Aston PA, et al. Insights from LGI1 and CASPR2 potassium channel complex auto-antibody subtyping. JAMA Neurol 2013;70(2):229-34. PMID 23407760
- 21
- Liewluck T, Klein CJ, Jone Jr LK. Cramp fasciculation syndrome in patients with and without neural autoantibodies. Muscle Nerve 2014;49(3):351-6. PMID 23836298
- 22
- Mertens HG, Zschocke S. Neuromyotonia. [Artilce in German] Klin Wochenschr 1965;43(17):917-25. PMID 5863557
- 23
- Michael S, Waters P, Irani SR. Stop testing for autoantibodies to the VGKC-complex:only request LGI1 and CASPR2. Pract Neurol 2020;20(5):377-84. PMID 32595134
- 24
- Nair AV, Mani A, Vijayaraghavan A, et al. Utility of stimulus induced after discharges in the evaluation of peripheral nerve hyperexcitability: old wine in a new bottle? J Peripher Nerv Syst 2021;26(1):90-8. PMID 33179828
- 25
- Nawfal O, Agha M, Makki A, Beydoun A. Refractory Morvan syndrome responsive to rituximab: a case report and review of the literature. Neuromuscul Disord 2022;32(8):682-6. PMID 35715317
- 26
- Niu J, Guan H, Cui L, Guan Y, Liu M. Afterdischarges following M waves in patients with voltage-gated potassium channels antibodies. Clin Neurophysiol Pract 2017;2:72-5. PMID 30214975
- 27
- Peeters K, Chamova T, Tournev I, Jordanova A. Axonal neuropathy with neuromyotonia: there is a HINT. Brain 2017;140:868-77. PMID 28007994
- 28
- Rashed HR, Milone M. The spectrum of rippling muscle disease. Muscle Nerve 2025;71(1):9-21. PMID 39370631
- 29
- Sansone VA. The dystrophic and nondystrophic myotonias. Continuum (Minneap Minn) 2016;22(6):1889-915. PMID 27922499
- 30
- Tahmoush AJ, Alonso RJ, Thamoush GP, Heiman-Patterson TD. Cramp fasciculation syndrome: a treatable hyperexcitable peripheral nerve disorder. Neurology 1991;41(7):1021-4. PMID 1648679
- 31
- Termsarasab T, Thammongkolchai T, Katirji B. Stiff person syndrome and related disorders. Springer: New York, 2020.
- 32
- Torbergsen T. Rippling muscle disease: a review. Muscle Nerve Suppl 2002;11:S103-7. PMID 12116294
- 33
- van Sonderen A, Ariño H, Petit-Pedrol M, et al. The clinical spectrum of Caspr2 antibody–associated disease. Neurology 2016a;87(5):521-8. PMID 27371488
- 34
- van Sonderen A, Thijs RD, Coenders EC, et al. Anti-LGI1 encephalitis. Clinical syndrome and long-term follow-up. Neurology 2016b;87(14):1449-56. PMID 27590293
- 35
- References especially recommended by the author or editor for general reading.
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Bashar Katirji MD
Dr. Katirji of Case Western Reserve University and the University Hospitals Cleveland Medical Center has no relevant financial relationships to disclose.
See Profile
Editor
-
Aravindhan Veerapandiyan MD
Dr. Veerapandiyan of University of Arkansas for Medical Sciences has no relevant financial relationships to disclose.
See Profile
ICD & OMIM codes
- ICD-10
-
- Isaacs syndrome: G71.19
- Morvan syndrome: G60.8
- ICD-11
-
- Isaacs syndrome: 8C71.4
- Morvan syndrome: 8E4A.3
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Developmental Malformations
Reducing body myopathy
May. 08, 2026
-
Neuromuscular Disorders
Zilucoplan
Apr. 23, 2026
-
Neuromuscular Disorders
Givinostat
Apr. 23, 2026
-
Neuropharmacology & Neurotherapeutics
Rozanolixizumab-noli
Apr. 23, 2026
-
Neuromuscular Disorders
Efgartigimod alfa and hyaluronidase-qvfc
Apr. 23, 2026
-
Neuropharmacology & Neurotherapeutics
Nusinersen
Apr. 23, 2026
-
Neuromuscular Disorders
Efgartigimod alfa-fcab
Apr. 23, 2026